Y mAbs Therapeutics

Company Profile

Y mAbs Therapeutics had its IPO on 2018-09-21 under the ticker symbol YMAB.

The company operates in the Healthcare sector and Biotechnology industry. Y mAbs Therapeutics has a staff strength of 147 employees.

Stock update

Shares of Y mAbs Therapeutics opened at $5.08 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.97 - $5.18, and closed at $5.01.

This is a -3.09% slip from the previous day's closing price.

A total volume of 121,621 shares were traded at the close of the day’s session.

In the last one week, shares of Y mAbs Therapeutics have slipped by -5.29%.

Y mAbs Therapeutics's Key Ratios

Y mAbs Therapeutics has a market cap of $230.75 million, indicating a price to book ratio of 2.056 and a price to sales ratio of 5.2098.

In the last 12-months Y mAbs Therapeutics’s revenue was $84.99 million with a gross profit of $57.70 million and an EBITDA of $-35933000. The EBITDA ratio measures Y mAbs Therapeutics's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Y mAbs Therapeutics’s operating margin was -43.3% while its return on assets stood at -15.46% with a return of equity of -33.09%.

In Q2, Y mAbs Therapeutics’s quarterly earnings growth was a positive 0% while revenue growth was a positive 92.2%.

Y mAbs Therapeutics’s PE and PEG Ratio

Forward PE

119.0476

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.94 per share while it has a forward price to earnings multiple of 119.0476 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Y mAbs Therapeutics’s profitability.

Y mAbs Therapeutics stock is trading at a EV to sales ratio of 2.5226 and a EV to EBITDA ratio of -0.8522. Its price to sales ratio in the trailing 12-months stood at 5.2098.

Y mAbs Therapeutics stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$132.40 million

Total Liabilities

$24.23 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Y mAbs Therapeutics ended 2024 with $132.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $132.40 million while shareholder equity stood at $104.68 million.

Y mAbs Therapeutics ended 2024 with $0 in deferred long-term liabilities, $24.23 million in other current liabilities, 4000.00 in common stock, $-448735000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $87.91 million and cash and short-term investments were $87.91 million. The company’s total short-term debt was $829,000 while long-term debt stood at $0.

Y mAbs Therapeutics’s total current assets stands at $115.78 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $19.12 million compared to accounts payable of $7.25 million and inventory worth $5.19 million.

In 2024, Y mAbs Therapeutics's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Y mAbs Therapeutics paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$5.01

52-Week High

$15.89

52-Week Low

$2.7

Analyst Target Price

$11.75

Y mAbs Therapeutics stock is currently trading at $5.01 per share. It touched a 52-week high of $15.89 and a 52-week low of $15.89. Analysts tracking the stock have a 12-month average target price of $11.75.

Its 50-day moving average was $5.97 and 200-day moving average was $5.68 The short ratio stood at 13.44 indicating a short percent outstanding of 0%.

Around 1330.2% of the company’s stock are held by insiders while 5905.3% are held by institutions.